Chronic kidney disease (CKD) is a serious health condition affecting 697.5 million people every year. It is characterized by reduced glomerular filtration, increased albuminuria, and gradual loss of renal function. Angiotensin-converting enzyme inhibitors (ACE) and angiotensin II receptor antagonists (ARB) are commonly used to treat CKD. While these drugs effectively reduce the progression of CKD, they do not decrease its all-cause mortality. However, sodium-glucose cotransporter 2 (SGLT2) inhibitors emerged as a promising alternative in reducing both the progression of CKD and its all-cause mortality.
To get detailed insights into the “ Role of SGLT2 Inhibitors in CKD ”, join the eminent renal and nephrology specialist, Dr. Bharat V. Shah , in our exclusive webinar on 9 th January 2023 , 6:00 PM IST onwards . Session highlights Chronic kidney disease is usually progressive.…
